Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBT (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EBT data on record, last reported at -$19.5 million in Q4 2024.

  • For Q4 2024, EBT rose 11.83% year-over-year to -$19.5 million; the TTM value through Dec 2024 reached -$86.6 million, up 8.05%, while the annual FY2024 figure was -$86.6 million, 8.05% up from the prior year.
  • EBT reached -$19.5 million in Q4 2024 per FHTX's latest filing, down from -$19.1 million in the prior quarter.
  • Across five years, EBT topped out at -$13.6 million in Q3 2023 and bottomed at -$29.9 million in Q1 2023.
  • Average EBT over 5 years is -$23.1 million, with a median of -$23.7 million recorded in 2021.
  • Peak YoY movement for EBT: tumbled 68.9% in 2021, then skyrocketed 47.2% in 2023.
  • A 5-year view of EBT shows it stood at -$21.1 million in 2020, then crashed by 35.11% to -$28.5 million in 2021, then fell by 1.33% to -$28.9 million in 2022, then grew by 23.42% to -$22.1 million in 2023, then increased by 11.83% to -$19.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for EBT were -$19.5 million in Q4 2024, -$19.1 million in Q3 2024, and -$23.0 million in Q2 2024.